BCAX Stock Summary and Trading Ideas (Bicara Therapeutics | NASDAQ:BCAX)

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Bicara Therapeutics trades on the NASDAQ stock market under the symbol BCAX.

As of February 24, 2026, BCAX stock price declined to $16.24 with 190,610 million shares trading.

BCAX has a beta of 1.95, meaning it tends to be more sensitive to market movements. BCAX has a correlation of 0.13 to the broad based SPY ETF.

BCAX has a market cap of $889.66 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that BCAX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

BCAX has outperformed the market in the last year with a price return of +24.9% while the SPY ETF gained +15.8%. However, in the short term, BCAX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -10.0% vs +4.6% return in SPY. But in the last 2 weeks, BCAX shares have fared better than the market returning +8.3% compared to SPY -1.0%.

BCAX support price is $15.68 and resistance is $17.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAX shares will trade within this expected range on the day.